Search clinical trials for: Selinexor combined with lenalidomide and rituximab

Total 1166 results

Ruijin Hospital

Not yet recruiting

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
Guangdong Provincial People's Hospital
Guangzhou First People's Hospital; Foshan First People's Hospital; Huizhou Municipal... and other collaborators

Recruiting

Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years (R2DLBCL80)

Diffuse Large B Cell Lymphoma | Age Over 80 Years

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Refractory Lymphoma | DLBCL | MYD88 Gene Mutation | Relapse | CD79A Gene Mutation | CD79B Gene Mutation
Ming Hou
Peking Union Medical College Hospital; Cancer Institute and Hospital, Chinese... and other collaborators

Completed

Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)

Purpura | Idiopathic Thrombocytopenic Purpura

China
MD Anderson International Spain SA
Celgene Corporation

Completed

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia (LLC-LENAR-08)

Chronic Lymphocytic Leukemia

Spain
Shandong University
The First Affiliated Hospital of Anhui Medical University; The Affiliated Hospital... and other collaborators

Completed

rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

Purpura | Idiopathic Thrombocytopenic Purpura

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma | Rituximab | Toripalimab

China
Ruijin Hospital
The First Affiliated Hospital of Nanchang University; Qilu Hospital of Shandong... and other collaborators

Recruiting

The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

Diffuse Large B-Cell Lymphoma

China
Antengene Corporation

Recruiting

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL (SWATCH)

Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin Lymphoma

China
Shandong University
China Medical University, China; The Affiliated Hospital of the Chinese Academy... and other collaborators

Withdrawn

Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Purpura | Idiopathic Thrombocytopenic Purpura

China
Eye & ENT Hospital of Fudan University

Recruiting

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Head and Neck Neoplasms | Metastatic Cancer | Recurrent Disease

China
The Affiliated Hospital of Qingdao University

Not yet recruiting

SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

DLBCL

China
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Sun Yat-sen... and other collaborators

Recruiting

Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL

Follicular Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma

China
Swiss Group for Clinical Cancer Research

Terminated

Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma

Lymphoma

Switzerland, Norway, Sweden
Fudan University

Completed

Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Lymphoma

China
Qilu Hospital of Shandong University

Recruiting

Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer

Colon Cancer

China
RenJi Hospital

Not yet recruiting

Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial

Efficacy and Safety
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

Lymphoma, Follicular

Italy
First Affiliated Hospital, Sun Yat-Sen University

Recruiting

Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

Primary Membranous Nephropathy

China
Anhui Provincial Hospital

Not yet recruiting

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

High Titers of Anti-HLA Antibody (MFI ≥5000)

China
Fudan University

Completed

Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

Double Expressor Lymphoma

China
Institut Paoli-Calmettes

Completed

Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma (R2)

Non-Hodgkin Lymphoma

France
Roswell Park Cancer Institute
Celgene

Completed

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant

Lymphoma | Leukemia
University of Bologna

Terminated

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Italy
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

Lymphoma

United States
LiNing

Not yet recruiting

The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer

Colorectal Neoplasms

China
Sun Yat-sen University
West China Hospital; Chongqing Medical University; Shanghai General Hospital,... and other collaborators

Active, not recruiting

Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma (PVP)

Glaucoma, Angle-Closure

China
Peter MacCallum Cancer Centre, Australia
AbbVie

Not yet recruiting

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)

Relapsed/Refractory Large B-cell Lymphoma

Australia
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue

Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)

Austria
Weill Medical College of Cornell University
Celgene

Completed

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
FENG Ji-feng
Chinese Anti-Cancer Association

Unknown

R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL

Diffuse Large B-cell Lymphoma

China
Kim, Seok Jin
Celltrion; Samyang Biopharmaceuticals Corporation

Recruiting

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. (Lemon-C)

Primary CNS Lymphoma

Korea, Republic of
Enterome

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

Follicular Lymphoma | Marginal Zone Lymphoma

United States, Italy, Spain
UMC Utrecht
Celgene Corporation

Completed

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) (REPEAT)

Multiple Myeloma

Netherlands
L.V. Prasad Eye Institute

Completed

Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy

Primary Congenital Glaucoma | Developmental Glaucoma | Infantile Glaucoma

India
Chronic Lymphocytic Leukemia Research Consortium
Celgene Corporation

Unknown

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | CLL | Untreated | First-Line | Front-line | Initial Therapy

United States
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
Xuhua Tan

Recruiting

Impact of Capsular Tension Ring Implantation on Intraocular Lens Position

Cataract | High Myopia

China
Henan Cancer Hospital

Recruiting

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Central Nervous System Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China
Karyopharm Therapeutics Inc

Recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Relapsed/Refractory Diffuse Large B-cell Lymphoma

United States, Spain, Israel, Italy, Poland, China, Austria
Yan Zhang, MD
Peking University First Hospital; Chinese PLA General Hospital; Peking University...

Recruiting

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Diffuse Large B Cell Lymphoma

China
Fundacion para la Investigacion Biomedica del Hospital...

Completed

Effectiveness of Invasive Electrostimulation Combined With an Exercise Program in Plantar Fasciitis

Fasciitis, Plantar

Spain
Assiut University

Completed

Phaco-Trabeculotomy Vs Phaco-Trabeculectomy (PDT vs PT)

Glaucoma | Glaucoma, Angle-Closure | Ophthalmopathy

Egypt
The Lymphoma Academic Research Organisation

Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

France
Tianjin Medical University Cancer Institute and...

Recruiting

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Innate Pharma

Completed

Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse (KIRIMID)

Patients With Multiple Myeloma Experiencing a | First or Second Relapse

United States
Università Vita-Salute San Raffaele

Recruiting

Restoring Neural Oscillatory Communication in Developmental Dyslexia

Developmental Dyslexia

Italy
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States

Search clinical trials for: Selinexor combined with lenalidomide and rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations